Skip to main content
Clinical Trials/NCT01797224
NCT01797224
Active, not recruiting
Not Applicable

Cimzia (certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project

University of California, San Diego1 site in 1 country925 target enrollmentMarch 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Crohn's Disease
Sponsor
University of California, San Diego
Enrollment
925
Locations
1
Primary Endpoint
Major malformations
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live born infants for five years after birth. With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be relevant to a medication exposure during pregnancy, and these include both easily recognizable defects which are visible at birth, as well as more subtle or delayed defects that may not be readily identifiable without special expertise and observation beyond the newborn period.

Detailed Description

The purpose of the OTIS Autoimmune Diseases in Pregnancy Project, Cimzia Pregnancy Exposure Registry is to follow pregnant women with or without a Cimzia approved indication who have or have not been treated with Cimzia during pregnancy to evaluate the possible effect of these diseases, and or this medication on the pregnancy outcome including child development and growth up to five years of age.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
March 2026
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christina Chambers

Professor, Co-Director Center for Promotion of Maternal Health and Infant Development

University of California, San Diego

Eligibility Criteria

Inclusion Criteria

  • Currently pregnant

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Major malformations

Time Frame: Duration of pregnancy and up to 1 year of life

The primary objective of the study is to evaluate the effect of certain medications when used in the first trimester of pregnancy with respect to major structural birth defects.

Secondary Outcomes

  • Minor malformations(At dysmorphological exam which will occur at one time point between birth and 5 years of age)
  • Pregnancy Outcome(Duration of pregnancy and up to 1 year of life)
  • Infant follow-up(Duration of pregnancy and up to 5 years of life)

Study Sites (1)

Loading locations...

Similar Trials